Clinical trials: c-MET
Irritable Bowel Syndrome With Constipation
A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation
The purpose of this study is to evaluate the safety and efficacy of linaclotide for the treatment of Irritable Bowel syndrome with Constipation (IBS-C), in children age 7-17 years.
- Trial name
- LIN-MD-63 (NCT02559817)
- Testing
- Linaclotide Dose A, Linaclotide Dose B, Linaclotide Dose C
- Where
- 48 sites in United States, Canada
- Volunteers
- 101 people
- Sponsor
- Forest Laboratories